Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current disease-modifying therapies in multiple sclerosis.

Bernd C Kieseier1, Hans-Peter Hartung

  • 1Department of Neurology, Heinrich-Heine-University, Moorenstrasse 5, 40225 Düsseldorf, Germany.

Seminars in Neurology
|August 2, 2003
PubMed
Summary

Interferon beta and glatiramer acetate are effective for relapsing-remitting multiple sclerosis (RRMS). These disease-modifying drugs, along with mitoxantrone, offer anti-inflammatory and immunomodulatory benefits for various MS types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

AI-driven reclassification of multiple sclerosis progression.

Nature medicine·2025
Same author

Targeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis.

Immunologic research·2024
Same author

Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.

Neurology·2024
Same author

A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.

Therapeutic advances in neurological disorders·2024

Area of Science:

  • Neurology
  • Immunology

Background:

  • Established efficacy of interferon beta and glatiramer acetate in treating relapsing-remitting multiple sclerosis (RRMS).
  • Interferon beta also shows efficacy in secondary-progressive multiple sclerosis (SPMS) and in patients with isolated syndromes at high risk for clinically definite multiple sclerosis (MS).
  • Mitoxantrone is an available disease-modifying drug for SPMS and severe RRMS cases.

Purpose of the Study:

  • To review the clinical utility of disease-modifying agents in multiple sclerosis (MS).
  • To focus on treatments with anti-inflammatory, immunomodulatory, and immunosuppressive properties.
  • To exclude symptomatic therapies from the review.

Main Methods:

  • Literature review of disease-modifying agents for multiple sclerosis.

Related Experiment Videos

  • Analysis of treatments based on their anti-inflammatory, immunomodulatory, and immunosuppressive mechanisms.
  • Exclusion of symptomatic therapies.

    • Main Results:

    • Interferon beta and glatiramer acetate are established treatments for RRMS.
    • Interferon beta is also effective for SPMS and high-risk isolated syndromes.
    • Mitoxantrone is indicated for SPMS and severe RRMS.

    Conclusions:

    • Disease-modifying agents play a crucial role in managing multiple sclerosis.
    • The reviewed agents offer distinct therapeutic benefits through immunomodulation and anti-inflammatory actions.
    • Further understanding of these agents' utility is essential for optimizing MS treatment strategies.